IL286742A - Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr - Google Patents

Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr

Info

Publication number
IL286742A
IL286742A IL286742A IL28674221A IL286742A IL 286742 A IL286742 A IL 286742A IL 286742 A IL286742 A IL 286742A IL 28674221 A IL28674221 A IL 28674221A IL 286742 A IL286742 A IL 286742A
Authority
IL
Israel
Prior art keywords
insertions
compounds
cancer cells
activity against
tumor activity
Prior art date
Application number
IL286742A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of IL286742A publication Critical patent/IL286742A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL286742A 2019-03-29 2021-09-27 Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr IL286742A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826843P 2019-03-29 2019-03-29
PCT/US2020/025228 WO2020205521A1 (en) 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions

Publications (1)

Publication Number Publication Date
IL286742A true IL286742A (en) 2021-10-31

Family

ID=72666976

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286742A IL286742A (en) 2019-03-29 2021-09-27 Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr

Country Status (13)

Country Link
US (2) US20220143023A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946293A4 (cg-RX-API-DMAC7.html)
JP (2) JP7650814B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210149103A (cg-RX-API-DMAC7.html)
CN (1) CN113939284A (cg-RX-API-DMAC7.html)
AU (1) AU2020254499A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019489A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131864A1 (cg-RX-API-DMAC7.html)
IL (1) IL286742A (cg-RX-API-DMAC7.html)
MX (1) MX2021011948A (cg-RX-API-DMAC7.html)
PH (1) PH12021552395A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110669WA (cg-RX-API-DMAC7.html)
WO (1) WO2020205521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110129434A (zh) * 2018-02-08 2019-08-16 埃提斯生物技术(上海)有限公司 胆汁中生物标志物在诊断恶性肿瘤中的应用
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
US20220143023A1 (en) * 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
JP7709384B2 (ja) * 2019-04-17 2025-07-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
BR112022015140A2 (pt) 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
UY39593A (es) * 2020-12-29 2022-07-29 Spectrum Pharmaceuticals Inc Tratamiento para tumores sólidos malignos
WO2022206929A1 (zh) * 2021-04-01 2022-10-06 上海医药集团股份有限公司 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用
WO2023015149A1 (en) * 2021-08-02 2023-02-09 Spectrum Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with poziotinib
KR20230063731A (ko) 2021-11-02 2023-05-09 주식회사 엘지에너지솔루션 전해액의 분할 주입을 포함하는 이차전지의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10308658B2 (en) * 2015-10-19 2019-06-04 Sunshine Lake Pharma Co., Ltd. Salt of EGFR inhibitor, crystalline form and uses thereof
BR112019010020A2 (pt) * 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
CA3076915A1 (en) * 2017-09-27 2019-04-04 AI Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors
CN111867586A (zh) * 2018-03-13 2020-10-30 得克萨斯州大学系统董事会 用于治疗具有egfr激活突变的癌症的方法
JP7386174B2 (ja) * 2018-03-27 2023-11-24 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Her2エクソン19変異を有するがん細胞に対する抗腫瘍活性を有する化合物
US20220143023A1 (en) * 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions

Also Published As

Publication number Publication date
EP3946293A1 (en) 2022-02-09
JP2025090740A (ja) 2025-06-17
US20250312348A1 (en) 2025-10-09
JP2022527788A (ja) 2022-06-06
CA3131864A1 (en) 2020-10-08
WO2020205521A1 (en) 2020-10-08
BR112021019489A2 (pt) 2022-02-08
AU2020254499A1 (en) 2021-10-28
EP3946293A4 (en) 2023-05-03
KR20210149103A (ko) 2021-12-08
CN113939284A (zh) 2022-01-14
PH12021552395A1 (en) 2022-06-13
JP7650814B2 (ja) 2025-03-25
US20220143023A1 (en) 2022-05-12
MX2021011948A (es) 2022-01-04
SG11202110669WA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
IL286576A (en) Compounds with antitumor activity against cancer cells containing exon 21 her2 insertions
EP3946293A4 (en) COMPOUNDS WITH ANTITUMORIC ACTIVITIES AGAINST CANCER CELLS WITH EGFR OR HER2 EXON 20 INSERTATIONS
IL277373A (en) Compounds with antitumor activity against cancer cells with a mutation in exon 19 of HER2
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
SG11202106435QA (en) Treating gastric cancer using ttfields combined with xelox or folfox
MX385562B (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.
MX393599B (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
EP4302784A3 (en) Anti-ntb-a antibodies and related compositions and methods
MX390435B (es) Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20.
PH12021552579A1 (en) Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations
GB201913030D0 (en) Treatment of hr deficient cancer
EP4031224A4 (en) MANDRIN WITH IMPROVED THREADABILITY
IL276235B2 (en) Use of Minfrain to reduce tumor growth
GB202108237D0 (en) Cancer methods
MX2018006776A (es) Usos de pirimido-piridazinonas para tratar el cancer.
EP3303363A4 (en) INTRAPATIENT GENOMHETEROGENICITY OF INDIVIDUAL CIRCULATIVE TUMOR CELLS (CTCS) RELATED TO PHENOTYPIC CTC HETEROGENICITY IN METASTASED, CASTING RESISTANT PROSTATE CANCER (MCRPC)
EP4045009A4 (en) METHOD FOR TREATING BREAST CANCER
EP3983063A4 (en) RADIATION SHIELDING FOR BRACHYTHERAPY
GB201918313D0 (en) Cells for treating cancer
MX2009010954A (es) Actividad antitumoral de temsirolimus en cancer celular renal papilar.
CA3269203A1 (en) Compounds with anti-tumor activity against kras mutated tumors
GB201821035D0 (en) Raising roof assemblies
IL316821A (en) Cancer treatment with NUC-7738
AU2024359870A1 (en) First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
HK40016016A (en) Optimized strategy for exon skipping modifications using crispr/cas9 with triple guide sequences